JP2007020586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007020586A5 JP2007020586A5 JP2006287210A JP2006287210A JP2007020586A5 JP 2007020586 A5 JP2007020586 A5 JP 2007020586A5 JP 2006287210 A JP2006287210 A JP 2006287210A JP 2006287210 A JP2006287210 A JP 2006287210A JP 2007020586 A5 JP2007020586 A5 JP 2007020586A5
- Authority
- JP
- Japan
- Prior art keywords
- microorganism
- gene
- virus
- cells
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000005700 microbiome Species 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 241000700605 Viruses Species 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 108060001084 Luciferase Proteins 0.000 claims description 2
- 239000005089 Luciferase Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 150000003672 ureas Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 40
- 241000700618 Vaccinia virus Species 0.000 claims 27
- 241001465754 Metazoa Species 0.000 claims 22
- 101150056927 F3 gene Proteins 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 210000004881 tumor cell Anatomy 0.000 claims 7
- 101150039660 HA gene Proteins 0.000 claims 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims 4
- 108020004440 Thymidine kinase Proteins 0.000 claims 4
- 238000003780 insertion Methods 0.000 claims 4
- 230000037431 insertion Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 108700008625 Reporter Genes Proteins 0.000 claims 3
- 101150003725 TK gene Proteins 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 230000008030 elimination Effects 0.000 claims 3
- 238000003379 elimination reaction Methods 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 231100000331 toxic Toxicity 0.000 claims 3
- 230000002588 toxic effect Effects 0.000 claims 3
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 108091006047 fluorescent proteins Proteins 0.000 claims 2
- 102000034287 fluorescent proteins Human genes 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- LPJXPACOXRZCCP-VIFPVBQESA-N (2s)-2-benzamidopentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 LPJXPACOXRZCCP-VIFPVBQESA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- SYMHUEFSSMBHJA-UHFFFAOYSA-N 6-methylpurine Chemical compound CC1=NC=NC2=C1NC=N2 SYMHUEFSSMBHJA-UHFFFAOYSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000053602 DNA Human genes 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 108700019961 Neoplasm Genes Proteins 0.000 claims 1
- 102000048850 Neoplasm Genes Human genes 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 241000710960 Sindbis virus Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 1
- 241000881055 Vaccinia virus LIVP Species 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 241000607598 Vibrio Species 0.000 claims 1
- 241000607626 Vibrio cholerae Species 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- QLTCHMYAEJEXBT-UHFFFAOYSA-N alpha-beta-D-glucopyranosyloxy-isobutyronitrile Natural products N#CC(C)(C)OC1OC(CO)C(O)C(O)C1O QLTCHMYAEJEXBT-UHFFFAOYSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000029918 bioluminescence Effects 0.000 claims 1
- 238000005415 bioluminescence Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- WOCXQMCIOTUMJV-UHFFFAOYSA-N cb1954 Chemical compound C1=C([N+]([O-])=O)C(C(=O)N)=CC(N2CC2)=C1[N+]([O-])=O WOCXQMCIOTUMJV-UHFFFAOYSA-N 0.000 claims 1
- 230000006037 cell lysis Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000013583 drug formulation Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- 150000008134 glucuronides Chemical class 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 239000003617 indole-3-acetic acid Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 231100001231 less toxic Toxicity 0.000 claims 1
- QLTCHMYAEJEXBT-ZEBDFXRSSA-N linamarin Chemical compound N#CC(C)(C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QLTCHMYAEJEXBT-ZEBDFXRSSA-N 0.000 claims 1
- CRTWQTRFSBJGLK-UHFFFAOYSA-N linamarin Natural products CC(C)(C#N)C1OC(CO)C(O)C(O)C1O CRTWQTRFSBJGLK-UHFFFAOYSA-N 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000007918 pathogenicity Effects 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229940118696 vibrio cholerae Drugs 0.000 claims 1
- 230000001018 virulence Effects 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101100218368 Aspergillus sojae axhA gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003246 corticosteroid Chemical class 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03013826A EP1489164A1 (en) | 2003-06-18 | 2003-06-18 | Recombinant vaccinia viruses with modified F3 genes, uses thereof |
| EP03013826.7 | 2003-06-18 | ||
| EP03018478A EP1512746B1 (en) | 2003-08-14 | 2003-08-14 | Method for the production of a polypeptide, RNA or other compound in tumor tissue |
| EP03018478.2 | 2003-08-14 | ||
| EP03024283A EP1526185B1 (en) | 2003-10-22 | 2003-10-22 | Use of a microorganism or cell to induce autoimmunization of an organism against a tumor |
| EP03024283.8 | 2003-10-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517504A Division JP3934673B1 (ja) | 2003-06-18 | 2004-06-18 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008017869A Division JP4294711B2 (ja) | 2003-06-18 | 2008-01-29 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
| JP2009136914A Division JP5342932B2 (ja) | 2003-06-18 | 2009-06-08 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007020586A JP2007020586A (ja) | 2007-02-01 |
| JP2007020586A5 true JP2007020586A5 (enExample) | 2007-07-12 |
| JP4961190B2 JP4961190B2 (ja) | 2012-06-27 |
Family
ID=34119412
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517504A Expired - Fee Related JP3934673B1 (ja) | 2003-06-18 | 2004-06-18 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
| JP2006287210A Expired - Fee Related JP4961190B2 (ja) | 2003-06-18 | 2006-10-23 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
| JP2008017869A Expired - Fee Related JP4294711B2 (ja) | 2003-06-18 | 2008-01-29 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
| JP2009136914A Expired - Fee Related JP5342932B2 (ja) | 2003-06-18 | 2009-06-08 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006517504A Expired - Fee Related JP3934673B1 (ja) | 2003-06-18 | 2004-06-18 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008017869A Expired - Fee Related JP4294711B2 (ja) | 2003-06-18 | 2008-01-29 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
| JP2009136914A Expired - Fee Related JP5342932B2 (ja) | 2003-06-18 | 2009-06-08 | 修飾組換えワクシニアウイルスおよびその他の微生物、その使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (11) | US7588767B2 (enExample) |
| EP (2) | EP2028270B9 (enExample) |
| JP (4) | JP3934673B1 (enExample) |
| CN (1) | CN100562570C (enExample) |
| AT (2) | ATE545699T1 (enExample) |
| AU (2) | AU2004289953B2 (enExample) |
| BR (1) | BRPI0411526A (enExample) |
| CA (1) | CA2527225C (enExample) |
| DE (1) | DE602004018927D1 (enExample) |
| MX (1) | MXPA05013879A (enExample) |
| RU (1) | RU2376371C2 (enExample) |
| SG (1) | SG179291A1 (enExample) |
| WO (1) | WO2005047458A2 (enExample) |
Families Citing this family (236)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0109515D0 (en) * | 2001-04-17 | 2001-06-06 | Neg Micon As | A method for transporting a set of large longitudinal items, a package system to be used by the method and use of such a package system |
| EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| EP1369491A1 (en) | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
| US20030228261A1 (en) * | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
| AU2003258168B2 (en) * | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| SG179291A1 (en) | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| US20070134202A1 (en) * | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
| US8221739B2 (en) | 2004-04-29 | 2012-07-17 | Botanic Oil Innovations, Inc. | Method of cancer treatment |
| CN103866018B (zh) | 2005-08-01 | 2016-05-25 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
| EP1933857A2 (en) * | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| CN103028120B (zh) | 2005-09-12 | 2015-08-12 | 俄亥俄州立大学研究基金会 | 用于诊断或治疗bcl2相关癌症的组合物和方法 |
| US20070077231A1 (en) * | 2005-09-30 | 2007-04-05 | Contag Christopher H | Immune effector cells pre-infected with oncolytic virus |
| WO2007053542A2 (en) * | 2005-11-01 | 2007-05-10 | Boston Life Sciences, Inc. | Methods and compositions for the prevention and regression of neovascularization |
| US8682619B2 (en) * | 2005-12-14 | 2014-03-25 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US8278094B2 (en) | 2005-12-14 | 2012-10-02 | The Invention Science Fund I, Llc | Bone semi-permeable device |
| US8734823B2 (en) * | 2005-12-14 | 2014-05-27 | The Invention Science Fund I, Llc | Device including altered microorganisms, and methods and systems of use |
| US20110183348A1 (en) * | 2010-01-22 | 2011-07-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Compositions and methods for therapeutic delivery with microorganisms |
| US20090311664A1 (en) * | 2005-12-22 | 2009-12-17 | Yuman Fong | Method for Detection of Cancer Cells Using Virus |
| ES2524018T3 (es) | 2006-01-05 | 2014-12-03 | The Ohio State University Research Foundation | Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares |
| EP2487260B1 (en) | 2006-01-05 | 2015-07-08 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| WO2007081720A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| EP2369012A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| CA2657030A1 (en) | 2006-07-13 | 2008-01-17 | The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
| US8071292B2 (en) | 2006-09-19 | 2011-12-06 | The Ohio State University Research Foundation | Leukemia diagnostic methods |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| JP5501766B2 (ja) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン |
| US8034560B2 (en) | 2007-01-31 | 2011-10-11 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML) |
| KR100858913B1 (ko) * | 2007-03-09 | 2008-09-17 | 한국과학기술원 | 부위특이적 변이에 의해 제조된 고수율의 ｌ－쓰레오닌생산균주 및 이를 이용한 ｌ－쓰레오닌의 제조방법 |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2008141226A2 (en) * | 2007-05-10 | 2008-11-20 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens |
| EP2150616A4 (en) | 2007-05-10 | 2011-07-27 | Univ Arizona | REGULATED ANTIGEN SYNTHESIS AND / OR REGULATED ATTENUATION FOR IMPROVING VACCINATE IMMUNOGENICITY AND / OR SAFETY |
| US8003364B2 (en) | 2007-05-14 | 2011-08-23 | Bavarian Nordic A/S | Purification of vaccinia viruses using hydrophobic interaction chromatography |
| NZ578960A (en) * | 2007-05-14 | 2012-11-30 | Bavarian Nordic As | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
| US20090081639A1 (en) * | 2007-05-31 | 2009-03-26 | Phil Hill | Assay for sensitivity to chemotherapeutic agents |
| PT2164862E (pt) * | 2007-06-08 | 2015-10-29 | Australian Poultry Crc Pty Ltd | Toxina de clostrídio netb |
| CA2690144A1 (en) | 2007-06-08 | 2008-12-18 | The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services | Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells |
| JP5213075B2 (ja) * | 2007-06-15 | 2013-06-19 | ジェネラックス・コーポレイション | 腫瘍の画像化および／または処置のための微生物 |
| US8053186B2 (en) | 2007-06-15 | 2011-11-08 | The Ohio State University Research Foundation | Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing |
| CA2693623A1 (en) * | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| ES2496172T3 (es) | 2007-07-31 | 2014-09-18 | The Ohio State University Research Foundation | Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B |
| AU2008283997B2 (en) | 2007-08-03 | 2014-04-10 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
| US7807180B2 (en) | 2007-08-21 | 2010-10-05 | University Of Massachusetts | Poxvirus methods and compositions |
| CN101836112A (zh) | 2007-08-22 | 2010-09-15 | 俄亥俄州立大学研究基金会 | 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物 |
| US8465755B2 (en) * | 2007-10-05 | 2013-06-18 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against enteric pathogens |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| CA2703707A1 (en) | 2007-10-26 | 2009-04-30 | The Ohio State University Research Foundation | Methods for identifying fragile histidine triad (fhit) interaction and uses thereof |
| BRPI0820576B1 (pt) * | 2007-11-19 | 2021-10-19 | Transgène S.A. | Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo |
| CA2705873C (en) * | 2007-11-19 | 2012-06-12 | Philippe Erbs | Poxviral oncolytic vectors |
| US8357486B2 (en) * | 2008-01-11 | 2013-01-22 | Genelux Corporation | Methods and compositions for detection of bacteria and treatment of diseases and disorders |
| CA2715036A1 (en) * | 2008-03-14 | 2009-09-17 | Retrotope, Inc. | Therapies for cancer using isotopically substituted lysine |
| WO2009114814A2 (en) | 2008-03-14 | 2009-09-17 | Retrotope, Inc. | Therapeutic substances that modulate genome methylation |
| US20110172107A1 (en) * | 2008-04-30 | 2011-07-14 | Fox Chase Cancer Center | Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby |
| US8825503B2 (en) * | 2008-05-15 | 2014-09-02 | Youdocs, Llc | Methods and systems for improving human health using targeted probiotics |
| EP2300023A2 (en) * | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| AU2009257410B2 (en) | 2008-06-11 | 2014-03-06 | Fudan University | Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
| NZ589981A (en) * | 2008-07-03 | 2012-11-30 | Univ Iowa State Res Found Inc | Cattle vaccines comprising a disrupted M. bovis bacterium |
| WO2010030293A1 (en) * | 2008-09-15 | 2010-03-18 | Gentron, Inc. | Methods, systems, and compositions for cancer diagnosis |
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| EP2326712B1 (en) * | 2008-09-19 | 2016-05-04 | ETAT FRANCAIS représenté par le Directeur central du Service de Santé des Armées | Viral strains derived from the vaccinia virus lister vacv-107 and uses thereof |
| WO2010045620A1 (en) | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
| US9163219B2 (en) * | 2009-04-14 | 2015-10-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Single expression vector for generation of a virus with a segmented genome |
| WO2010135563A1 (en) | 2009-05-22 | 2010-11-25 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium and methods of antigen and nucleic acid delivery |
| US9045742B2 (en) * | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
| EP2477499B1 (en) | 2009-09-14 | 2018-04-11 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
| JP5960060B2 (ja) | 2009-11-23 | 2016-08-02 | ジ・オハイオ・ステート・ユニバーシティ | 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法 |
| US9062297B2 (en) | 2010-01-13 | 2015-06-23 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Yersinia pestis vaccine |
| EP2526185A4 (en) | 2010-01-22 | 2013-07-24 | Univ Arizona | BACTERIUM WITH REGULATED RFAH NUCLEIC ACID |
| WO2011150421A2 (en) * | 2010-05-28 | 2011-12-01 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
| WO2012065049A1 (en) | 2010-11-12 | 2012-05-18 | The Ohio State University Research Foundation | Materials and methods related to microrna-21, mismatch repair, and colorectal cancer |
| CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
| RU2447150C1 (ru) * | 2010-11-26 | 2012-04-10 | Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН | Средство для генной терапии злокачественных опухолей |
| CN103429258B (zh) | 2011-01-04 | 2016-03-09 | 新罗杰公司 | 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性 |
| US8664192B2 (en) | 2011-03-07 | 2014-03-04 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
| CN102685768B (zh) | 2011-03-08 | 2016-02-03 | 华为技术有限公司 | 心跳消息的处理方法、心跳周期的获取方法及接入网设备 |
| WO2012142529A2 (en) | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| US9260519B2 (en) | 2011-06-17 | 2016-02-16 | President And Fellows Of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
| CN102286415B (zh) * | 2011-09-07 | 2014-03-05 | 天津工业生物技术研究所 | 琥珀酸高产菌株及其应用 |
| WO2013052915A2 (en) | 2011-10-05 | 2013-04-11 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER |
| MY167390A (en) * | 2011-11-18 | 2018-08-16 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| CN104619353A (zh) | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
| US8956873B2 (en) * | 2012-01-13 | 2015-02-17 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
| US10076579B2 (en) | 2012-01-13 | 2018-09-18 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
| US9023612B2 (en) | 2012-01-13 | 2015-05-05 | Bell Biosystems, Inc. | Eukaryotic cells with artificial endosymbionts for multimodal detection |
| US8828681B2 (en) | 2012-01-13 | 2014-09-09 | Bell Biosystems, Inc. | Host cells with artificial endosymbionts |
| JP2015511121A (ja) | 2012-01-20 | 2015-04-16 | ジ・オハイオ・ステート・ユニバーシティ | 浸潤性および予後に関する乳がんバイオマーカーシグネチャー |
| CA2867156C (en) * | 2012-03-08 | 2017-08-08 | Trimed, Incorporated | System and method for treating a fractured bone |
| US20140087362A1 (en) | 2012-03-16 | 2014-03-27 | Aladar A. Szalay | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| WO2013154760A1 (en) * | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
| US9303264B2 (en) | 2012-05-18 | 2016-04-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Photosynthetic microorganisms expressing thermostable lipase |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| WO2014145785A1 (en) | 2013-03-15 | 2014-09-18 | Bell Biosystems, Llc | Host cells with artificial endosymbionts |
| CN103589656A (zh) * | 2013-05-28 | 2014-02-19 | 湖北省农业科学院畜牧兽医研究所 | 猪传染性胸膜肺炎放线杆菌血清1型锌离子结合蛋白a缺失株及其构建方法和应用 |
| US9580718B2 (en) | 2013-06-17 | 2017-02-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Attenuated live bacteria with increased acid resistance and methods of use thereof |
| GB201310917D0 (en) * | 2013-06-19 | 2013-07-31 | Cancer Res Inst Royal | Vaccinia virus for gene-directed enzyme prodrug therapy |
| SG11201601488VA (en) | 2013-09-03 | 2016-03-30 | Bell Biosystems Inc | Host cell modification with artificial endosymbionts |
| US20150064759A1 (en) * | 2013-09-05 | 2015-03-05 | Braskem S.A. | Modified microorganism and methods of using same for producing 2-propanol and1-propanol and/or 1,2-propanediol |
| US10028649B2 (en) * | 2013-12-02 | 2018-07-24 | Welch Allyn, Inc. | Digital colposcope system |
| CN104694541A (zh) * | 2013-12-09 | 2015-06-10 | 江苏命码生物科技有限公司 | 禽流感病毒miRNA及其鉴定、检测和应用 |
| AU2014373792A1 (en) * | 2013-12-30 | 2016-07-07 | Genomatix | Genomic rearrangements associated with prostate cancer and methods of using the same |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| CN103743903A (zh) * | 2014-01-08 | 2014-04-23 | 江苏省苏北人民医院 | 肝癌术后复发预测标志物Capn4检测方法及试剂盒 |
| EP3825411A1 (en) | 2014-06-18 | 2021-05-26 | Clear Gene, Inc. | Methods, compositions, and devices for rapid analysis of biological markers |
| EP3169779A4 (en) * | 2014-07-15 | 2018-03-21 | Bell Biosystems, Inc. | Eukaryotic cells with artificial endosymbionts for multimodal detection |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| CN105586319B (zh) * | 2014-10-20 | 2021-01-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 复制型痘苗病毒载体艾滋病疫苗 |
| RU2716821C2 (ru) | 2014-10-24 | 2020-03-17 | Калиди Биотерапьютикс, Инк. | Комбинированный иммунотерапевтический подход к лечению рака |
| EP3237607B1 (en) | 2014-12-22 | 2020-05-06 | Veterinærinstituttet | Salmon gill poxvirus |
| EP3247085A4 (en) * | 2015-01-18 | 2018-07-11 | LG Electronics Inc. | Broadcast signal transmission apparatus, broadcast signal receiving apparatus, broadcast signal transmission method, and broadcast signal receiving method |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR101835180B1 (ko) | 2015-03-18 | 2018-03-06 | 아주대학교산학협력단 | 재조합 BTG2(B cell translocation gene 2) 단백질 및 이의 생산방법 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| EA201800148A1 (ru) * | 2015-08-11 | 2019-01-31 | Калиди Биотерапьютикс, Инк. | Оспенная вакцина для лечения рака |
| US20200208173A1 (en) * | 2015-10-30 | 2020-07-02 | Seracare Life Sciences, Inc. | Adenovirus control virus |
| US11401558B2 (en) | 2015-12-18 | 2022-08-02 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| CN106978397A (zh) * | 2016-01-18 | 2017-07-25 | 上海宇研生物技术有限公司 | 一种人dc-cik免疫活性细胞及其制备方法 |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| CN108770344B (zh) | 2016-03-28 | 2024-01-05 | 胡敏杰 | 抗癌溶瘤病毒联合治疗和优良反应者选择平台 |
| KR102824067B1 (ko) | 2016-04-15 | 2025-06-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| EP3443000B1 (en) | 2016-04-15 | 2025-11-12 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| UA126380C2 (uk) | 2016-05-30 | 2022-09-28 | Астеллас Фарма Інк. | Генно-інженерний вірус вісповакцини |
| KR102306553B1 (ko) | 2016-07-21 | 2021-09-30 | 코오롱생명과학 주식회사 | 재조합 백시니아 바이러스 및 이의 용도 |
| CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| CN118853594A (zh) * | 2016-08-09 | 2024-10-29 | 希望之城 | 嵌合痘病毒组合物及其用途 |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| US20190330613A1 (en) * | 2016-11-24 | 2019-10-31 | Cathay R&D Center Co., Ltd. | Control of protein to protein interactions of acid decarboxylase |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2018106754A1 (en) | 2016-12-07 | 2018-06-14 | Md Biosciences, Inc. | Methods of synergistic treatment of cancer |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| RU2658606C1 (ru) * | 2017-01-26 | 2018-06-21 | Рашит Накипович Кадыров | Штамм streptococcus pyogenes n b-7612, продуцент комплекса биологически активных соединений, обладающих иммуностимулирующими свойствами |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| US20190134105A1 (en) * | 2017-11-09 | 2019-05-09 | Richard Postrel | Method for Precise Identification, Targeting and Delivery of Directed Therapies with the Use of Bacteria for the Destruction of Cancerous Cells |
| LT3596116T (lt) | 2017-03-16 | 2023-11-10 | Alpine Immune Sciences, Inc. | Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai |
| CN110809581A (zh) | 2017-03-16 | 2020-02-18 | 高山免疫科学股份有限公司 | Pd-l2变体免疫调节蛋白及其用途 |
| CA3054068A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| US12275994B2 (en) | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| CN107164338A (zh) * | 2017-06-27 | 2017-09-15 | 镇江市卫克生物科技有限公司 | 一种重组溶瘤病毒及其应用 |
| US10851350B1 (en) | 2017-06-27 | 2020-12-01 | Genelux Corporation | Bioreactor production of virus from adherent cells |
| CN117106037B (zh) * | 2017-06-30 | 2025-07-25 | 弗拉芒区生物技术研究所 | 新颖蛋白孔 |
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| MX2020004540A (es) | 2017-10-18 | 2020-08-03 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados. |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| CA3086009A1 (en) * | 2017-12-20 | 2019-06-27 | Radimmune Therapeutics, Inc. | Antibodies to centrin-1, methods of making, and uses thereof |
| RU2020124143A (ru) | 2017-12-22 | 2022-01-24 | Кодадженикс Инк. | Рекомбинантный вирус с областью деоптимизированной пары кодонов и его применение для лечения рака |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN108489941B (zh) * | 2018-01-31 | 2021-07-27 | 吉林大学 | 溴酚蓝在作为检测牛胰岛素淀粉样纤维探针和作为牛胰岛素淀粉样纤维抑制剂方面的应用 |
| HUE065696T2 (hu) * | 2018-03-06 | 2024-06-28 | Danisco Us Inc | Acetát-termelés csökkentése PAB1-et túltermelõ élesztõvel |
| BR112020018188A2 (pt) | 2018-03-08 | 2021-02-02 | Codagenix Inc. | flavivírus atenuados |
| CN110386985B (zh) * | 2018-04-19 | 2022-09-20 | 四川大学华西医院 | 一种肿瘤靶向性促凋亡融合蛋白及其用途 |
| KR20210028149A (ko) * | 2018-05-17 | 2021-03-11 | 투불 메디테라피 피.씨. | 진단적 혈액 검사 |
| ES2966045T3 (es) | 2018-06-04 | 2024-04-18 | Calidi Biotherapeutics Inc | Vehículos basados en células para la potenciación de la terapia viral |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CN108676890B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统 |
| CN109172613B (zh) * | 2018-08-14 | 2022-04-22 | 景岳生物科技(中国)有限公司 | 含乳杆菌死菌培养物的皮肤外用组合物及其于促进伤口愈合及降低疤痕产生的用途 |
| WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CN116162654A (zh) | 2018-09-15 | 2023-05-26 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫疗法的重组痘病毒 |
| PH12021550661A1 (en) | 2018-09-26 | 2022-03-21 | Astellas Pharma Inc | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019371238A1 (en) * | 2018-10-30 | 2021-06-03 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
| AU2019377141B2 (en) | 2018-11-06 | 2024-06-06 | Calidi Biotherapeutics (Nevada), Inc. | Enhanced systems for cell-mediated oncolytic viral therapy |
| CN109546191B (zh) * | 2018-11-07 | 2021-06-18 | 大连理工大学 | 一种混合基质型阴离子膜及其制备方法 |
| CN113891934A (zh) | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| CA3125020A1 (en) * | 2019-01-07 | 2020-07-16 | Kalivir Immunotherapeutics, Inc. | Methods of treating cancer |
| TW202038994A (zh) | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| CA3129883A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| US11717542B2 (en) | 2019-02-22 | 2023-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Using tumor-navigating Salmonella to modulate tumor metabolism |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CN109810991B (zh) * | 2019-03-02 | 2021-11-12 | 昆明理工大学 | 二氢蝶酸合酶基因folP的用途 |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| US20220160888A1 (en) * | 2019-04-01 | 2022-05-26 | Industry-University Cooperation Foundation Hanyang University | Cp2c-targeting peptide-based anticancer agent |
| CN109957551B (zh) * | 2019-04-03 | 2021-03-23 | 浙江省医学科学院 | 表达人β-防御素2的重组痘苗病毒及其应用 |
| JP2022531976A (ja) * | 2019-05-15 | 2022-07-12 | コーダ－ジェニックス・インコーポレイテッド | 弱毒化黄熱ウイルス及びがんの処置のためのその使用 |
| JP2022534783A (ja) * | 2019-06-03 | 2022-08-03 | イミュノルクス インターナショナル コーポレーション | 疾患を処置するための天然痘ワクチン及び幹細胞 |
| KR20220054819A (ko) | 2019-08-29 | 2022-05-03 | 아스테라스 세이야쿠 가부시키가이샤 | 유전자 변형 암용해 백시니아 바이러스 및 이의 사용 방법 |
| CN110585427B (zh) * | 2019-09-06 | 2023-06-06 | 刘慧宁 | 提高机体免疫力的组合物及在抗成人t细胞白血病或鼻咽癌中的应用 |
| CN110713962B (zh) * | 2019-09-06 | 2022-06-21 | 南京农业大学 | 一株高产丙二酰辅酶a的基因工程菌及其构建方法和应用 |
| US11271912B2 (en) * | 2019-09-27 | 2022-03-08 | Envistacom, Llc | Anonymous communication over virtual, modular, and distributed satellite communications network |
| CN110551672B (zh) * | 2019-09-30 | 2023-05-23 | 中国科学院成都生物研究所 | 高产反式-4-羟基-l-脯氨酸的大肠杆菌菌株及其构建方法 |
| CN110564867B (zh) * | 2019-10-10 | 2022-06-24 | 扬州大学 | 一种秦川牛cfl1基因的snp分子标记及其检测方法 |
| CN110747174A (zh) * | 2019-10-30 | 2020-02-04 | 青岛宁逸生物科技有限公司 | 一种用于肿瘤治疗的重组病毒 |
| WO2021116943A1 (en) | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| CN111254219B (zh) * | 2019-12-27 | 2023-08-04 | 上海华盈生物医药科技有限公司 | 一种用于进行病毒包装效率检测的方法 |
| CN111019877B (zh) * | 2019-12-31 | 2022-04-19 | 浙江工业大学 | 一种产l-半胱氨酸的基因工程菌、构建方法及应用 |
| BR112022013521A2 (pt) | 2020-01-09 | 2022-09-13 | Pfizer | Vírus vaccinia recombinante |
| EP4110801A1 (en) * | 2020-02-25 | 2023-01-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| CN116368221A (zh) | 2020-04-22 | 2023-06-30 | 因达普塔治疗公司 | 自然杀伤(nk)细胞组合物及其生成方法 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| CN111875699B (zh) * | 2020-07-03 | 2022-07-05 | 江南大学 | 一种提高枯草芽孢杆菌卵清蛋白表达量的方法 |
| US20220033784A1 (en) | 2020-07-14 | 2022-02-03 | Pfizer Inc. | Recombinant vaccinia virus |
| CN111705144B (zh) * | 2020-07-17 | 2022-11-18 | 扬州大学 | 一个与猪背膘厚关联的znf2基因内sine转座子多态分子标记及其检测方法 |
| CN111913584B (zh) * | 2020-08-19 | 2022-04-01 | 福州大学 | 一种基于手势识别的鼠标光标控制方法及系统 |
| CN112011555A (zh) * | 2020-09-09 | 2020-12-01 | 西南大学 | 一种调控沙门氏菌自裂解的重组基因、重组质粒及其应用 |
| EP4222250A1 (en) | 2020-10-02 | 2023-08-09 | Genelux Corporation | Bioreactor production of virus from adherent cells |
| CN112149041B (zh) * | 2020-10-20 | 2022-12-16 | 贵州电网有限责任公司 | 一种基于psd-bpa数据及图形化交互技术的故障分析方法 |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| CN114584999B (zh) * | 2020-11-30 | 2023-08-15 | 中国移动通信集团山西有限公司 | 一种监测系统、方法、设备及计算机存储介质 |
| CN113322275A (zh) * | 2021-03-24 | 2021-08-31 | 中国人民解放军空军军医大学 | 一种巨噬细胞的CRISPR/Cas9表观编辑系统、方法、编辑后的巨噬细胞和应用 |
| CN115261460A (zh) * | 2021-04-02 | 2022-11-01 | 武汉儿童医院 | Hnrnpa2b1基因表达水平检测物在产后抑郁症检测中的应用及检测系统 |
| CN113238045B (zh) * | 2021-04-27 | 2021-12-28 | 南方医科大学南方医院 | Crmp2及抗crmp2抗体的应用 |
| CN113363963B (zh) * | 2021-05-20 | 2022-05-20 | 南昌大学 | 一种改进麻雀搜索算法优化三相sapf直流侧控制方法 |
| CN113249286B (zh) * | 2021-05-25 | 2023-12-08 | 洛阳华荣生物技术有限公司 | 一种构建l-肌氨酸生产菌的方法 |
| CN113322213B (zh) * | 2021-07-09 | 2022-05-13 | 吉林大学 | 一种具有改善记忆障碍功能的副干酪乳杆菌Jlus66菌剂和应用 |
| CN114395574B (zh) * | 2022-01-18 | 2023-08-11 | 长沙爱科博生物科技有限公司 | 一种猪流行性腹泻病毒融合蛋白及其编码基因与应用 |
| CN115304679B (zh) * | 2022-01-21 | 2024-07-16 | 郑州大学第一附属医院 | 一种促进t细胞分化的限制型car及其应用 |
| US20230233299A1 (en) * | 2022-01-27 | 2023-07-27 | EdgeEndo, LLC | Dental, endodontic, and periodontic treatment methods and systems |
| CN114540521B (zh) * | 2022-03-23 | 2022-09-02 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 具有降糖降脂功效的植物乳杆菌84-3特异性分子靶标及其检测方法 |
| CN114774468B (zh) * | 2022-04-20 | 2022-12-20 | 温氏食品集团股份有限公司 | 一种等位基因分子标记及抗蓝耳病猪群体组建方法 |
| CN115011601B (zh) * | 2022-06-27 | 2023-07-21 | 山东大学齐鲁医院 | 一种干扰JUND表达的shRNA、重组腺相关病毒载体及其应用 |
| KR20250048615A (ko) | 2022-07-08 | 2025-04-09 | 바이로미슬, 인크. | 종양용해 백시니아 바이러스 및 재조합 바이러스 및 그의 사용 방법 |
| CN117625547B (zh) * | 2022-08-25 | 2024-06-28 | 广州百吉生物制药有限公司 | 联合表达gpx4的新一代嵌合抗原受体及其应用 |
| CN115838803A (zh) * | 2022-09-29 | 2023-03-24 | 上海中医药大学附属龙华医院 | 结直肠癌患者预后及对免疫检查点抑制剂应答效率的生物标志物及其应用 |
| CN117757704B (zh) * | 2022-12-19 | 2024-08-27 | 元素驱动(杭州)生物科技有限公司 | 一种提高支链氨基酸（bcaa）产量的方法及菌株构建 |
| CN116309507B (zh) * | 2023-03-29 | 2025-11-18 | 西南大学 | 注意力机制下对ctp进行特征融合的ais病灶预测方法 |
| CN116622577B (zh) * | 2023-05-26 | 2023-10-27 | 山东奈思健康科技有限责任公司 | 一种促进col1a2和col3a1表达提高胶原蛋白合成的后生元及其制备方法 |
| CN117603892B (zh) * | 2023-09-08 | 2025-12-05 | 吉林大学 | oahs基因缺失株及其在预防猪链球菌2型感染中的应用 |
| CN117269496B (zh) * | 2023-09-27 | 2024-08-13 | 山东大学齐鲁医院 | 一种评估胆管癌预后的生物标志物及其应用 |
| CN117589991B (zh) * | 2024-01-18 | 2024-03-29 | 天津云检医学检验所有限公司 | 一种用于乳腺癌患者her2表达状态鉴定的生物标志物、模型、试剂盒及用途 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
| CN119876203B (zh) * | 2025-03-25 | 2025-08-12 | 宁波大学 | 过表达细菌素合成调控基因及其重组植物乳植杆菌的构建方法和应用 |
| CN119931940B (zh) * | 2025-04-08 | 2025-07-29 | 上海交通大学医学院附属仁济医院 | 增强i型经典树突状细胞分化效率和存活时长的方法 |
| CN120060476A (zh) * | 2025-04-25 | 2025-05-30 | 湖南省人民医院(湖南师范大学附属第一医院) | 一种前列腺癌奥拉帕利治疗耐药标志物及其应用 |
Family Cites Families (204)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US29023A (en) * | 1860-07-03 | Cornelius j | ||
| US213007A (en) * | 1879-03-04 | Improvement in safety-pins | ||
| US83293A (en) * | 1868-10-20 | Improvement in button-hole cutters | ||
| US31628A (en) * | 1861-03-05 | Improvement in sewing-machines | ||
| US31643A (en) * | 1861-03-05 | Bons l | ||
| US165477A (en) * | 1875-07-13 | Improvement in smelting-furnaces | ||
| US161788A (en) * | 1875-04-06 | Improvement in bird-cages | ||
| US86906A (en) * | 1869-02-16 | Improvement in velocipedes | ||
| US101480A (en) * | 1870-04-05 | Improvement in hand seed-planter | ||
| US44384A (en) * | 1864-09-27 | Improved carpet-fastening | ||
| US54865A (en) * | 1866-05-22 | Improvement in cow-milkers | ||
| US228261A (en) * | 1880-06-01 | lewis | ||
| US160970A (en) * | 1875-03-16 | Improvement in key-rings | ||
| US31681A (en) * | 1861-03-12 | Puhchifg-machine | ||
| US76622A (en) * | 1868-04-14 | Bobeet john gaines | ||
| US228330A (en) * | 1880-06-01 | Advertising checker-board | ||
| US59400A (en) * | 1866-11-06 | Improvement | ||
| US165465A (en) * | 1875-07-13 | Improvement in paper-weights | ||
| US8025A (en) * | 1851-04-08 | Apparatus eor boltiitg flouk | ||
| US213741A (en) * | 1879-04-01 | Improvement in portable platforms for fire and other ladders | ||
| US69491A (en) * | 1867-10-01 | Newark | ||
| US9015A (en) * | 1852-06-15 | Manufacture of granular fuel from brush-wood and twigs | ||
| US33617A (en) * | 1861-10-29 | Improvement in grain-separators | ||
| US160410A (en) * | 1875-03-02 | Improvement in carbureters or hydrocarbon-diffusers | ||
| US143861A (en) * | 1873-10-21 | Improvement in picture-frames | ||
| JPS5535004Y2 (enExample) | 1975-07-28 | 1980-08-19 | ||
| JPS542336A (en) * | 1977-06-06 | 1979-01-09 | Meiji Seika Kaisha Ltd | Preventive and remedy for viral diseases |
| JPS5535004A (en) | 1978-09-02 | 1980-03-11 | Wakunaga Yakuhin Kk | Cell-immunity activator and its preparation |
| EP0037441B1 (en) | 1980-03-10 | 1984-05-09 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein |
| US4315914A (en) * | 1980-04-04 | 1982-02-16 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof |
| US4442203A (en) * | 1981-06-30 | 1984-04-10 | Massachusetts Institute Of Technology | Gene amplification assay for detecting tumor promoters |
| US5378457A (en) * | 1981-12-24 | 1995-01-03 | Virogenetics Corporation | Interferon sensitive recombinant poxvirus vaccine |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US5155020A (en) * | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US4778759A (en) * | 1982-07-09 | 1988-10-18 | Boyce, Thompson Institute For Plant Research, Inc. | Genetic engineering in cyanobacteria |
| US7045313B1 (en) * | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5221623A (en) * | 1986-07-22 | 1993-06-22 | Boyce Thompson Institute For Plant Research, Inc. | Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms |
| DE3789766T2 (de) | 1986-07-22 | 1994-09-29 | Texas A & M University Syst | Verwendung von bakteriellen luciferase strukturellen genen zum klonieren und zur steuerung der genexpression in mikroorganismen, sowie zur etikettierung und identifizierung von genetisch gebildeten organismen. |
| US5866136A (en) * | 1986-08-01 | 1999-02-02 | Commonwealth Scientific And Industrial Organisation | Recombinant vaccine |
| US6007806A (en) | 1986-08-13 | 1999-12-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor |
| US5283187A (en) * | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| CA1341251C (en) * | 1988-02-12 | 2001-06-12 | David Bernard Boyle | Pox virus vectors |
| US5650148A (en) * | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
| ATE219519T1 (de) * | 1989-01-23 | 2002-07-15 | Chiron Corp | Rekombinanttherapien für infektionen und hyperproliferative störungen |
| WO1990013658A1 (en) | 1989-04-28 | 1990-11-15 | The University Of Alberta | Plant hormone regulated expression of genetically engineered gene products in plant cells |
| AU6877991A (en) | 1989-11-28 | 1991-06-26 | Universite Laval | A method of inactivating human immunodeficiency virus |
| US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
| US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
| US5830702A (en) * | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| AU672359B2 (en) * | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
| CA2105277C (en) | 1991-03-07 | 2006-12-12 | William I. Cox | Genetically engineered vaccine strain |
| US5212082A (en) * | 1991-03-13 | 1993-05-18 | New York University | Genetically modified tyrosine hydroxylase and uses thereof |
| DK0585368T3 (da) * | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
| US5800829A (en) * | 1991-04-25 | 1998-09-01 | Brown University Research Foundation | Methods for coextruding immunoisolatory implantable vehicles with a biocompatible jacket and a biocompatible matrix core |
| US5776943A (en) * | 1991-05-14 | 1998-07-07 | American Home Products Corporation | Rapamycin metabolites |
| US5718902A (en) * | 1991-06-17 | 1998-02-17 | The Regents Of The University Of California | Double recombinant vaccinia virus vaccines |
| GB9114468D0 (en) * | 1991-07-04 | 1991-08-21 | Wellcome Found | Antibody production |
| US5411860A (en) * | 1992-04-07 | 1995-05-02 | The Johns Hopkins University | Amplification of human MDM2 gene in human tumors |
| DE69330640T2 (de) * | 1992-05-29 | 2002-07-04 | Vivorx, Inc. | Mikroverkapselung von zellen |
| CA2137449A1 (en) * | 1992-06-16 | 1993-12-23 | David J. Dall | Recombinant entomopoxvirus |
| WO1994010302A1 (de) | 1992-10-29 | 1994-05-11 | Boehringer Mannheim Gmbh | Amplifizierbarer vektor gegen hiv replikation |
| DE9302762U1 (de) * | 1993-02-25 | 1993-04-15 | Kelm, Eckehart, 8031 Gilching | Verstelleinrichtung für ein Hebeschiebedach |
| CA2169292C (en) * | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US6491905B1 (en) * | 1993-09-14 | 2002-12-10 | The Uab Research Foundation | Recombinant bacterial cells for delivery of PNP to tumor cells |
| FR2710536B1 (fr) | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
| US6416754B1 (en) * | 1994-03-03 | 2002-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
| US6984513B2 (en) | 1994-03-03 | 2006-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
| US5550050A (en) * | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US6093700A (en) | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
| CA2190290C (en) | 1994-05-13 | 2011-07-05 | Michael J. Mastrangelo | A method of inducing an immune response using vaccinia virus recombinants |
| JPH07313187A (ja) | 1994-05-24 | 1995-12-05 | Sagami Chem Res Center | 抗体作製法 |
| US6455673B1 (en) * | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5650135A (en) | 1994-07-01 | 1997-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
| US6217847B1 (en) * | 1994-07-01 | 2001-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
| US5776747A (en) | 1994-07-20 | 1998-07-07 | Cytotherapeutics, Inc. | Method for controlling the distribution of cells within a bioartificial organ using polycthylene oxide-poly (dimethylsiloxane) copolymer |
| US5853385A (en) | 1994-08-26 | 1998-12-29 | Cytotherapeutics, Inc. | Encapsulated PC12 cell transplants for treatment of Parkinson's disease |
| US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| EP0789774A2 (en) | 1994-10-03 | 1997-08-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| JP3907698B2 (ja) * | 1994-10-03 | 2007-04-18 | アメリカ合衆国 | 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物 |
| US5693533A (en) | 1994-12-07 | 1997-12-02 | The Goodwin Institue For Cancer Research | Human breast carcinoma cell line capable of production of a spontaneously metastasizing tumor in animals for use in anticancer drug testing |
| US6503703B1 (en) * | 1995-05-19 | 2003-01-07 | Mount Sinai School Of Medicine Of New York University | Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication |
| US5704910A (en) * | 1995-06-05 | 1998-01-06 | Nephros Therapeutics, Inc. | Implantable device and use therefor |
| US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5646298A (en) * | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
| US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US20020160970A1 (en) * | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US20030033617A1 (en) * | 1996-04-10 | 2003-02-13 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US5710137A (en) * | 1996-08-16 | 1998-01-20 | The Trustees Of Columbia University In The City Of New York | Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| US5842431A (en) | 1997-02-19 | 1998-12-01 | Wu; Chong-Ming | Rotating shuttle and presser plate arrangement |
| US6251384B1 (en) * | 1997-04-28 | 2001-06-26 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
| JP2001517090A (ja) * | 1997-04-28 | 2001-10-02 | アンチキャンサー インコーポレーテッド | マーカーとして緑色蛍光タンパク質（ｇｆｐ）を利用するがん転移モデル |
| US6232523B1 (en) * | 1997-04-28 | 2001-05-15 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
| US6884414B1 (en) * | 1997-04-30 | 2005-04-26 | Mount Sinai School Of Medicine Of New York University | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents |
| US6265557B1 (en) | 1997-05-09 | 2001-07-24 | Loma Linda University Medical Center | ABO histo-blood group O alleles of the baboon |
| US6713284B2 (en) * | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6080849A (en) * | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| NZ518945A (en) | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| US6099848A (en) * | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| US6106826A (en) * | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
| DK1895010T3 (da) | 1997-12-22 | 2011-11-21 | Oxford Biomedica Ltd | Vektorer baseret på virus for infektiøs hesteanæmi (eiav) |
| US6065557A (en) * | 1998-04-01 | 2000-05-23 | Von Keyserling; Peter H. | Power assist assembly for wheeled vehicles |
| US6713293B1 (en) | 1999-02-08 | 2004-03-30 | Friedrich Grummt | Encapsulated cells containing an amplified expression vector as a drug delivery device |
| US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| AU4246900A (en) | 1999-04-15 | 2000-11-02 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6511967B1 (en) * | 1999-04-23 | 2003-01-28 | The General Hospital Corporation | Use of an internalizing transferrin receptor to image transgene expression |
| EP1180157B1 (en) * | 1999-05-28 | 2012-11-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| US6627190B2 (en) | 1999-07-12 | 2003-09-30 | Saint Louis University | Recombinant adenovirus vectors that are replication-competent in tert-expressing cells |
| US6544781B1 (en) | 1999-07-15 | 2003-04-08 | The General Hospital Corporation | Non-defective Epstein-Barr viral vector |
| EP1416971A4 (en) | 1999-08-16 | 2004-05-12 | Uab Research Foundation | GENTRANSFER PRESENTATION AND THEIR USE |
| AU7572900A (en) | 1999-08-26 | 2001-03-19 | Vion Pharmaceuticals, Inc. | Compositions and methods for delivery of an agent using attenuated salmonella containing phage |
| JP4669180B2 (ja) | 1999-09-08 | 2011-04-13 | ゼノジェン コーポレイション | ルシフェラーゼ発現カセットおよび使用法 |
| AU7607900A (en) | 1999-09-22 | 2001-04-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| BR0014491A (pt) * | 1999-10-04 | 2004-03-09 | Vion Pharmaceuticals Inc | Bactérias atenuadas marcadas para tumor, composição farmacêutica, uso de bactérias atenuadas, e, proteina de fusão |
| CA2386806A1 (en) | 1999-10-04 | 2001-04-12 | Vion Pharmaceuticals, Inc. | Non-invasive tumor imaging by tumor-targeted bacteria |
| WO2001024637A1 (en) | 1999-10-04 | 2001-04-12 | Vion Pharmaceuticals, Inc. | Methods for treating solid tumors with irradiation and bacteria |
| MXPA02004736A (es) | 1999-11-12 | 2003-01-28 | Oncolytics Biotech Inc | Virus para el tratamiento de trastornos proliferativos celulares. |
| US7094532B2 (en) | 1999-12-29 | 2006-08-22 | Vanderbilt University | Genetic mutation underlying orthostatic intolerance and diagnostic and therapeutic methods relating thereto |
| US6589531B1 (en) * | 2000-01-21 | 2003-07-08 | The Regents Of The University Of California | Recombinant yellow fever virus and method of use thereof |
| AU3457101A (en) * | 2000-01-26 | 2001-08-07 | Univ Loma Linda | Method for the evaluation of implantable materials |
| US6448073B1 (en) * | 2000-01-28 | 2002-09-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| JP4021197B2 (ja) | 2000-03-17 | 2007-12-12 | アンチキャンサー， インコーポレイテッド | 遺伝子発現の全身光学イメージングとその使用 |
| DE10013511A1 (de) * | 2000-03-20 | 2001-10-11 | Brand Gmbh & Co Kg | Mehrkanal-Pipettiereinrichtung sowie Pipettenschaft dafür |
| WO2001075182A1 (fr) | 2000-04-04 | 2001-10-11 | Nippon Steel Corporation | Profile en acier lamine en forme de h a microstructure uniforme et proprietes mecaniques uniformes ; procede de fabrication |
| CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| CA2342040C (en) * | 2000-09-21 | 2012-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anaerobic bacterium as a drug for cancer gene therapy |
| JP3642755B2 (ja) | 2000-09-21 | 2005-04-27 | 純 天野 | 嫌気性菌を用いた遺伝子治療用医薬 |
| US7118740B1 (en) * | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
| AR035227A1 (es) | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
| ATE392551T1 (de) * | 2001-02-22 | 2008-05-15 | Alfmeier Praez Ag | Stellglied aus gedächtnismetall mit verbesserter temperaturregelung |
| US20040091995A1 (en) * | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| EP1404375A1 (en) * | 2001-07-09 | 2004-04-07 | Anticancer, Inc. | Imaging infection using fluorescent protein as a marker |
| EP1281772A1 (en) | 2001-07-31 | 2003-02-05 | Aladar A. Szalay | Light-emitting microorganisms and cells for tumour diagnosis/therapy |
| EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
| US20030198627A1 (en) * | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| US6840758B2 (en) * | 2001-10-26 | 2005-01-11 | Mold-Masters Limited | Valve bushing assembly |
| US7344710B2 (en) | 2001-11-21 | 2008-03-18 | The Johns Hopkins University | Combination bacteriolytic therapy for the treatment of tumors |
| EP1450854A2 (en) * | 2001-11-30 | 2004-09-01 | Isis Innovation Limited | Vaccine |
| US20060110407A1 (en) | 2001-12-05 | 2006-05-25 | Shelley Stopera | Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection |
| CN101869716B (zh) | 2001-12-31 | 2013-12-11 | 抗癌公司 | 监视细菌肿瘤治疗的系统 |
| WO2003063593A1 (en) | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
| JP2005531507A (ja) * | 2002-03-02 | 2005-10-20 | ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法 |
| WO2003078640A2 (en) | 2002-03-15 | 2003-09-25 | Baxter International Inc. | Recombinant drug-sensitive vaccinia virus as smallpox vaccine |
| US20030213007A1 (en) | 2002-03-27 | 2003-11-13 | Slattery Charles Wilbur | Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof |
| US7425449B2 (en) | 2002-04-30 | 2008-09-16 | The Regents Of The University Of California | Site specific Listeria integration vectors and methods for using the same |
| JP2005527240A (ja) | 2002-05-29 | 2005-09-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 弱毒リステリア種とこれを使用する方法 |
| EP1369491A1 (en) * | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
| US20030228261A1 (en) | 2002-06-05 | 2003-12-11 | Aladar Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
| WO2004000236A2 (en) | 2002-06-25 | 2003-12-31 | The Ohio State University Research Foundation | Modified sodium iodide symporter proteins and genes for imaging and cancer therapy |
| US7355162B2 (en) * | 2002-07-02 | 2008-04-08 | Optitune Plc | Optical wavelength measuring device using guiding body and diffractive structure |
| AU2003258168B2 (en) * | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| US20040136992A1 (en) | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
| US7318917B2 (en) | 2002-09-06 | 2008-01-15 | Vanderbilt University | Rapid assays for neurotransmitter transporters |
| CA2500661A1 (en) | 2002-10-01 | 2004-04-15 | Chiron Corporation | Anti-cancer and anti-infectious disease compositions and methods for using same |
| WO2004044175A2 (en) | 2002-11-12 | 2004-05-27 | Anticancer, Inc. | Fluorescence guided cell capture |
| WO2004098534A2 (en) | 2003-02-24 | 2004-11-18 | Therion Biologics Corporation | Methods for delivering angiogenic modulators using pox viruses |
| CN102836420B (zh) * | 2003-03-03 | 2014-03-12 | 得克萨斯州大学系统董事会 | 包含mda-7的组合物和方法 |
| US8452294B2 (en) | 2003-04-23 | 2013-05-28 | Qualcomm Incorporated | In-band ate indicator methods and apparatus |
| SG179291A1 (en) * | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| EP1489164A1 (en) | 2003-06-18 | 2004-12-22 | Genelux GmbH | Recombinant vaccinia viruses with modified F3 genes, uses thereof |
| EP1512746B1 (en) | 2003-08-14 | 2009-10-07 | Genelux Corporation | Method for the production of a polypeptide, RNA or other compound in tumor tissue |
| EP1526185B1 (en) | 2003-10-22 | 2012-09-12 | Genelux Corporation | Use of a microorganism or cell to induce autoimmunization of an organism against a tumor |
| WO2005057488A2 (en) | 2003-12-03 | 2005-06-23 | Anticancer, Inc. | Modular system for multi-color, whole body fluorescence imaging |
| KR20070003879A (ko) | 2004-01-26 | 2007-01-05 | 안티캔서, 인코포레이티드 | 휴대용 관찰 시스템을 사용한 전신 이미징 |
| WO2005094878A1 (ja) | 2004-03-31 | 2005-10-13 | Genomidea Inc. | 抗腫瘍作用を有する組成物 |
| US20060063993A1 (en) * | 2004-08-09 | 2006-03-23 | Dejin Yu | Method and apparatus for non-invasive measurement of blood analytes |
| US20080095744A1 (en) | 2004-11-02 | 2008-04-24 | Parker Jacqueline N | Methods and Compositions for Cytokine Expression and Treatment of Tumors |
| US20060193832A1 (en) | 2005-02-04 | 2006-08-31 | University Of Iowa Research Foundation | Use of the sodium iodine symporter to effect uptake of iodine |
| JP2006260179A (ja) * | 2005-03-17 | 2006-09-28 | Matsushita Electric Ind Co Ltd | トラックボール装置 |
| EP1924604B1 (en) | 2005-08-17 | 2011-11-30 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Human monoclonal antibodies that specifically bind igf-ii |
| US20090311664A1 (en) | 2005-12-22 | 2009-12-17 | Yuman Fong | Method for Detection of Cancer Cells Using Virus |
| TW200819540A (en) | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| ES2299362B1 (es) | 2006-07-11 | 2009-04-01 | Bestile, S.L. | Baldosa para revestimiento y pavimentacion. |
| EP2043529A4 (en) | 2006-07-12 | 2016-10-05 | Niti Surgical Solutions Ltd | COMPRESSION ASSEMBLIES AND APPLICATORS FOR USE WITH THE SAME |
| DE102006034854A1 (de) | 2006-07-25 | 2008-01-31 | Ovd Kinegram Ag | Verfahren zur Erzeugen einer Lasermarkierung in einem Sicherheitsdokument sowie derartiges Sicherheitsdokument |
| US7947255B2 (en) | 2006-08-09 | 2011-05-24 | Vanderbilt University | Fluorescent substrates for neurotransmitter transporters |
| US7569396B1 (en) * | 2006-09-08 | 2009-08-04 | Purplecow Llc | Caffeine detection using internally referenced competitive assays |
| WO2008043851A1 (en) | 2006-10-13 | 2008-04-17 | N.V. Organon | A non-homogeneous quencher free assay method for the noradrenaline transporter |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| US20090081639A1 (en) | 2007-05-31 | 2009-03-26 | Phil Hill | Assay for sensitivity to chemotherapeutic agents |
| JP5213075B2 (ja) | 2007-06-15 | 2013-06-19 | ジェネラックス・コーポレイション | 腫瘍の画像化および／または処置のための微生物 |
| CA2693623A1 (en) | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| US8357486B2 (en) * | 2008-01-11 | 2013-01-22 | Genelux Corporation | Methods and compositions for detection of bacteria and treatment of diseases and disorders |
| EP2300023A2 (en) * | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2012142529A2 (en) | 2011-04-15 | 2012-10-18 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| WO2013052915A2 (en) | 2011-10-05 | 2013-04-11 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| US20140087362A1 (en) * | 2012-03-16 | 2014-03-27 | Aladar A. Szalay | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| US20130280170A1 (en) | 2012-04-20 | 2013-10-24 | Aladar A. Szalay | Imaging methods for oncolytic virus therapy |
| US20140086976A1 (en) * | 2012-08-20 | 2014-03-27 | Aladar A. Szalay | Compositions containing protein polymers and vaccinia virus, and methods of use thereof |
| WO2014055960A1 (en) * | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| US20140271549A1 (en) | 2013-03-15 | 2014-09-18 | Aladar A. Szalay | Use of Antibiotics to Enhance Treatment With Therapeutic Viruses |
-
2004
- 2004-06-18 SG SG2007190150A patent/SG179291A1/en unknown
- 2004-06-18 JP JP2006517504A patent/JP3934673B1/ja not_active Expired - Fee Related
- 2004-06-18 CA CA2527225A patent/CA2527225C/en not_active Expired - Lifetime
- 2004-06-18 US US10/872,156 patent/US7588767B2/en active Active
- 2004-06-18 WO PCT/US2004/019866 patent/WO2005047458A2/en not_active Ceased
- 2004-06-18 AT AT08019998T patent/ATE545699T1/de active
- 2004-06-18 BR BRPI0411526-0A patent/BRPI0411526A/pt not_active IP Right Cessation
- 2004-06-18 DE DE602004018927T patent/DE602004018927D1/de not_active Expired - Lifetime
- 2004-06-18 CN CNB2004800236108A patent/CN100562570C/zh not_active Expired - Lifetime
- 2004-06-18 AT AT04816752T patent/ATE420160T1/de not_active IP Right Cessation
- 2004-06-18 EP EP08019998A patent/EP2028270B9/en not_active Expired - Lifetime
- 2004-06-18 EP EP04816752A patent/EP1644492B1/en not_active Expired - Lifetime
- 2004-06-18 RU RU2006100679/13A patent/RU2376371C2/ru not_active IP Right Cessation
- 2004-06-18 MX MXPA05013879A patent/MXPA05013879A/es active IP Right Grant
- 2004-06-18 AU AU2004289953A patent/AU2004289953B2/en not_active Ceased
-
2005
- 2005-09-27 US US11/238,025 patent/US7588771B2/en not_active Expired - Lifetime
-
2006
- 2006-09-27 US US11/529,662 patent/US7662398B2/en not_active Expired - Lifetime
- 2006-10-23 JP JP2006287210A patent/JP4961190B2/ja not_active Expired - Fee Related
-
2007
- 2007-04-25 US US11/796,027 patent/US8021662B2/en not_active Expired - Fee Related
- 2007-04-25 US US11/796,028 patent/US20070202572A1/en not_active Abandoned
-
2008
- 2008-01-29 JP JP2008017869A patent/JP4294711B2/ja not_active Expired - Fee Related
- 2008-04-17 US US12/148,542 patent/US8323959B2/en not_active Expired - Fee Related
- 2008-12-24 AU AU2008264201A patent/AU2008264201B2/en not_active Ceased
-
2009
- 2009-06-08 JP JP2009136914A patent/JP5342932B2/ja not_active Expired - Fee Related
- 2009-07-28 US US12/462,074 patent/US7754221B2/en not_active Expired - Lifetime
- 2009-10-26 US US12/589,694 patent/US8221769B2/en not_active Expired - Fee Related
-
2012
- 2012-07-10 US US13/507,572 patent/US8784836B2/en not_active Expired - Lifetime
-
2014
- 2014-06-11 US US14/301,813 patent/US9492534B2/en not_active Expired - Fee Related
-
2016
- 2016-10-21 US US15/331,742 patent/US10463730B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007020586A5 (enExample) | ||
| US20230137548A1 (en) | Neural stem cell-mediated cancer treatment | |
| US12291726B2 (en) | A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter | |
| RU2006100679A (ru) | Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение | |
| Taguchi et al. | Current status of clinical trials assessing oncolytic virus therapy for urological cancers | |
| US20140350087A9 (en) | Oncovector Nucleic Acid Molecules and Methods of Use | |
| US20160296612A1 (en) | Methods and compositions for treating or preventing cancer | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| RS58146B1 (sr) | Onkolitički herpes simpleks virus i njegova terapeutska upotreba | |
| CN105722518A (zh) | 使用溶瘤腺病毒的脑癌治疗 | |
| Varela et al. | Gene therapy for high grade glioma: the clinical experience | |
| JP2002500662A (ja) | 核酸と細胞外マトリックスを崩壊させる物質とを組み合わせた遺伝子治療用組合せ製剤 | |
| CN109475613A (zh) | 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达 | |
| EP4414381A1 (en) | Il-10 monomer fusion protein and use thereof | |
| CN117534767A (zh) | 靶向cldn6嵌合抗原受体巨噬细胞及其制备方法和应用 | |
| Li et al. | Oncolytic virus Ad-TD-nsIL-12 inhibits glioma growth and reprograms the tumor immune microenvironment | |
| Zhou et al. | An update on the clinical trial research of immunotherapy for glioblastoma | |
| Jiang et al. | Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors | |
| CN115804853A (zh) | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 | |
| CN114632149A (zh) | 溶瘤病毒和免疫调节剂在协同抑制晚期肝癌中的应用 | |
| CN117660368A (zh) | 表达趋化因子ccl19的重组溶瘤流感病毒及应用 | |
| CN119768512A (zh) | 突变的流感病毒、药物组合物及用途 | |
| CN108504688A (zh) | 调控自杀基因在肝脏肿瘤细胞中特异性表达的操纵系统 | |
| Denies et al. | Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice | |
| CN116670172A (zh) | 表达免疫检查点抑制剂的癌症特异性反式剪接核酶及其用途 |